Mallinckrodt to buy CNS Therapeutics for $100 million
- September 24, 2012
Hazelwood-based Mallinckrodt, the pharmaceuticals business of Covidien, announced a definitive agreement to acquire CNS Therapeutics Inc. for $100 million. St. Paul, Minn.-based CNS Therapeutics Inc. is a privately held specialty pharmaceutical ... Read More